| Not Yet Recruiting | SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma Locally Advanced or Metastatic Renal Cell Carcinoma | Phase 2 | 2027-02-01 |
| Not Yet Recruiting | Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal C Locally Advanced Rectal Cancer | Phase 2 | 2026-08-10 |
| Not Yet Recruiting | Timing Optimization of Immunotherapy During Neoadjuvant Chemotherapy for Locally Advanced Nasopharyngeal Carci Locally Advanced Nasopharyngeal Carcinoma | Phase 2 | 2026-03-01 |
| Not Yet Recruiting | Clinical Study on the Prevention and Treatment of Radiation Vaginitis With Triethanolamine Cream Vaginitis, Radiotherapy Induced Mucositis | Phase 4 | 2026-03-01 |
| Not Yet Recruiting | CROSSROAD: Treatment Regimen Switch - Re-induction Chemotherapy vs. Direct Radiotherapy in LANPC With Inadequa Nasopharyngeal Carcinoma | — | 2026-02-01 |
| Recruiting | SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer Cervical Cancer | Phase 2 | 2026-01-28 |
| Recruiting | Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II) Non-Small Cell Lung Cancer | Phase 4 | 2026-01-15 |
| Not Yet Recruiting | Sintilimab-Nimotuzumab Induction Followed by Chemoradiation-Nimotuzumab in LA-HNSCC: Single-Arm Phase II Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-SCCHN) | Phase 2 | 2026-01-10 |
| Not Yet Recruiting | MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC Nasopharyngeal Carcinoma, Local Recurrence | Phase 2 | 2026-01-01 |
| Not Yet Recruiting | Risk-Adapted Omission of Level Va Irradiation in Nasopharyngeal Carcinoma Nasopharyngeal Carcinoma by AJCC V9 Stage | Phase 3 | 2026-01-01 |
| Not Yet Recruiting | The Efficacy of Preoperative Oral Administration of Lactobacillus Reuteri Combined With Preoperative Neoadjuva HCC - Hepatocellular Carcinoma | N/A | 2025-12-20 |
| Not Yet Recruiting | Ivarmacitinib in Advanced Solid Tumors: A Prospective, Two-Cohort, Two-Phase Exploratory Study in Patients Dis Patients With Advanced Solid Tumors Who Discontinued Treatment Due to irAE | Phase 2 | 2025-12-10 |
| Recruiting | SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases Locally Advanced Rectal Cancer With Liver Metastases | Phase 2 | 2025-12-01 |
| Not Yet Recruiting | Hetrombopag for the Prevention of ADC-Induced Thrombocytopenia in Breast Cancer: An Exploratory, Dual-Cohort, CTIT-Chemotherapy Induced Thrombocytopenia, Breast Cancer | Phase 2 | 2025-11-30 |
| Not Yet Recruiting | A Clinical Study of Hetrombopag for Prevention of Thrombocytopenia Induced by Gemcitabine Plus Cisplatin in th Nasopharyngeal Carcinoma (NPC), CTIT-Chemotherapy Induced Thrombocytopenia | Phase 2 | 2025-11-30 |
| Recruiting | Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Breast Cancer | Phase 3 | 2025-11-15 |
| Not Yet Recruiting | Efficacy and Safety of Serplulimab Combined With Etoposide and Cisplatin as Neoadjuvant Therapy in Limited-Sta Small-Cell Carcinoma of the Esophageal | Phase 2 | 2025-09-01 |
| Not Yet Recruiting | A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and Chemotherap Vunakizumab, Adebrelimab, Small Cell Lung Cancer | Phase 2 | 2025-09-01 |
| Not Yet Recruiting | Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients Early Breast Cancer, Adjuvant Therapy, Hormone Receptor Positive / HER2-negative Breast Cancer | Phase 2 | 2025-09-01 |
| Recruiting | Neoadjuvant Iparomlimab and Tuvonralimab Plus Chemotherapy-eclipse for Locally Advanced Cervical Cancer (NICE- Locally Advanced Cervical Cancer | Phase 2 | 2025-08-21 |
| Not Yet Recruiting | Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or S Esophagus Cancer | Phase 2 | 2025-08-01 |
| Not Yet Recruiting | Watch-and-Wait After Immunochemotherapy in Locally Recurrent Nasopharyngeal Carcinoma Recurrent Nasopharyngeal Carcinoma | — | 2025-08-01 |
| Not Yet Recruiting | Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Metastatic Colorectal Cancer With Left-sided Primary Tumor, Immunotherapy | Phase 2 | 2025-07-30 |
| Recruiting | Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomize Gastric Cancer | Phase 3 | 2025-06-07 |
| Not Yet Recruiting | SLND Versus Non-Dissection Following ESD for T1a Stage Esophageal Squamous Cell Carcinoma Esophageal Cancer | N/A | 2025-06-01 |
| Not Yet Recruiting | Tislelizumab as Single-Agent Neoadjuvant Immunotherapy in Resectable Esophageal Squamous Cell Carcinoma Esophagus Cancer | Phase 2 | 2025-05-15 |
| Not Yet Recruiting | Reducing Dose and Irradiated Volume in Cervical Prophylactic Irradiation for Nasopharyngeal Cancer Nasopharyngeal Carcinoma | Phase 3 | 2025-04-01 |
| Not Yet Recruiting | PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM Colorectal Cancer Liver Metastasis | Phase 2 | 2025-03-01 |
| Not Yet Recruiting | A Study of Adebelimab Combined With Chemotherapy as a First-line Treatment Sequential Treatment for Extensive- Extensive-Stage Small Cell Lung Cancer | Phase 2 | 2025-02-01 |
| Not Yet Recruiting | A Prospective, Open-label, Single-arm Phase II Clinical Study of Fruquintinib Combined With S-1 for the Treatm Colorectal Cancer | Phase 2 | 2025-02-01 |
| Not Yet Recruiting | A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and Small Cell Lung Cancer Extensive Stage | Phase 2 | 2025-01-25 |
| Recruiting | CTV Delineation Based Solely on Geometric Expansion From GTV in Nasopharyngeal Carcinoma Nasopharyngeal Carcinoma by AJCC V8 Stage | Phase 3 | 2025-01-01 |
| Not Yet Recruiting | A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemothera Biliary Tract Cancer | Phase 2 | 2025-01-01 |
| Not Yet Recruiting | SBRT Combined With Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular Carcino Hepatocellular Carcinoma, SBRT, Immune Checkpoint Blockade | Phase 2 | 2025-01-01 |
| Recruiting | Safety Comparison of Total Laparoscopic Proximal Gastrectomy With or Without Preservation of the Celiac Branch Gastric Cancer | N/A | 2025-01-01 |
| Not Yet Recruiting | Effect of Nurse-Led Individualized Follow-Up Intervention on Patients With Nasopharyngeal Carcinoma Nasopharyngeal Carcinoma | N/A | 2024-11-01 |
| Not Yet Recruiting | Chemotherapy Plus EGFR Monoclonal Antibody in Patients With Liver Metastases From Colorectal Cancer With ctDNA Liver Metastases of Colorectal Cancer | Phase 2 | 2024-11-01 |
| Not Yet Recruiting | Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EG Leptomeningeal Metastasis | Phase 2 | 2024-10-01 |
| Not Yet Recruiting | Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian Ca Platinum-resistant Ovarian Cancer (PROC), Immunotherapy | Phase 2 | 2024-10-01 |
| Not Yet Recruiting | Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic E Esophageal Cancer | Phase 2 | 2024-09-30 |
| Recruiting | Exploring the Efficacy, Safety and Cost-effectiveness Analysis of Cadonilimab in the Treatment of Cervical Can Cervical Cancer | — | 2024-09-07 |
| Not Yet Recruiting | The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy Immunotherapy Gastroesophageal Junction | Phase 2 | 2024-08-01 |
| Completed | Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal Cancer Mid-low Rectal Cancer | Phase 2 | 2024-07-12 |
| Not Yet Recruiting | Short-course Radiotherapy Combined With Sintilimab for Neoadjuvant Treatment of Esophageal Squamous Cell Carci Esophageal Squamous Cell Carcinoma | Phase 2 | 2024-06-17 |
| Not Yet Recruiting | Phase II Study of Different Doses of Radiotherapy Combined With Sintilimab in the Treatment of Locally Advance Esophageal Squamous Cell Carcinoma | Phase 2 | 2024-06-17 |
| Recruiting | Clinical Observation of Drug Retention Enema in Preventing Acute Radiation-induced Rectal Injury Radiation Injuries, Rectal Diseases | N/A | 2024-06-11 |
| Not Yet Recruiting | A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide Colo-rectal Cancer | Phase 2 | 2024-06-01 |
| Not Yet Recruiting | Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma Metastatic Nasopharyngeal Carcinoma, Intermittent Systematic Chemotherapy | Phase 2 | 2024-05-01 |
| Active Not Recruiting | A Study of SYS6010 in Combination With SYH2051 in Patients With Advanced Colorectal Cancer and Other Gastroint Colorectal Cancer, Gastric Cancer (GC), Gastrointestinal Tumors | N/A | 2024-04-18 |
| Recruiting | A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcino Esophageal Squamous Cell Carcinoma | Phase 2 | 2024-03-20 |
| Unknown | Metronomic Oral Vinorelbine Combination With Tislelizumab in EGFR/ALK-negative Advanced NSCLC EGFR/ ALK-negative Advanced NSCLC | Phase 2 | 2024-02-07 |
| Not Yet Recruiting | Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer Endometrial Cancer, Endometrial Adenocarcinoma | Phase 2 | 2024-02-01 |
| Not Yet Recruiting | The Correlation Between HRD Detection and the Efficacy of PARP Inhibitors in Ovarian Cancer Ovarian Neoplasms | — | 2024-01-31 |
| Unknown | SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cance EGFR Positive Non-small Cell Lung Cancer | EARLY_Phase 1 | 2024-01-10 |
| Unknown | Radiotherapy Combined With TKI and Anti-PD-1 Antibody for Stage IIIA Hepatocellular Carcinoma Stage IIIA Hepatocellular Carcinoma | N/A | 2024-01-09 |
| Not Yet Recruiting | MRI Radiomics Combined With Pathomics on the Prediction of Molecular Classification and Prognosis of Endometri Endometrial Neoplasms | — | 2024-01-01 |
| Not Yet Recruiting | MRI-based Signatures for Survival Prediction in Cervical Cancer With Radiotherapy Cervical Cancer, Radiotherapy, Prognostic Model | — | 2024-01-01 |
| Unknown | Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer Gastric Cancer | Phase 2 | 2024-01-01 |
| Not Yet Recruiting | Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer Cervical Cancer | Phase 2 | 2024-01-01 |
| Not Yet Recruiting | Induction Chemotherapy and Immunotherapy Combined Radiotherapy With or Without Concurrent Chemotherapy for Sta Nasopharyngeal Carcinoma | Phase 3 | 2024-01-01 |
| Recruiting | Neoadjuvant Treatment of Neuroendocrine Cervix Carcinomar With Camrelizumab Combined With Etoposide and Cispla Carcinoma, Cervix Carcinoma | Phase 2 | 2023-12-28 |
| Unknown | Nasopharyngeal Carcinoma Treated With Reduced Volume Intensity Modulated Radiation Therapy:10-Year Outcome and Nasopharyngeal Carcinoma | — | 2023-12-01 |
| Not Yet Recruiting | A Predictive Model for Early Metastasis in Cervical Cancer Patients After Radiotherapy Cervical Cancer, Radiotherapy, Distant Metastasis | — | 2023-12-01 |
| Unknown | Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer Colorectal Cancer | Phase 2 | 2023-11-19 |
| Not Yet Recruiting | A Diagnostic Nomogram for Predicting Vaginal Invasion in Cervical Cancer Cervix Carcinoma | — | 2023-11-01 |
| Recruiting | Efficacy and Safety of AK104 Combined With Chemotherapy and Recombinant Human Adenovirus 5 Injection in Cervic Cervical Cancer Recurrent | Phase 2 | 2023-10-11 |
| Not Yet Recruiting | PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors Advanced Solid Tumor | Phase 1 / Phase 2 | 2023-10-10 |
| Not Yet Recruiting | Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer Immunotherapy | Phase 2 | 2023-09-01 |
| Not Yet Recruiting | Phase II Study of Reuse of Oxaliplatin Hypersensitivity in Gastrointestinal Tumors Gastrointestinal Tumors | Phase 2 | 2023-09-01 |
| Recruiting | Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian C Ovarian Neoplasms, Ovarian Diseases | Phase 2 | 2023-08-01 |
| Not Yet Recruiting | A Study to Evaluate Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellula Hepatocellular Carcinoma | Phase 2 | 2023-08-01 |
| Recruiting | Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer. Esophageal Neoplasms, Esophageal Diseases, Digestive System Neoplasms | Phase 2 | 2023-08-01 |
| Unknown | Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric C Gastric Cancer | Phase 2 | 2023-07-01 |
| Unknown | XH-30002 Capsule Combined With Afatinib Tablets for the Treatment of Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma | Phase 1 | 2023-06-01 |
| Not Yet Recruiting | Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung Ca Small Cell Lung Cancer | Phase 1 / Phase 2 | 2023-06-01 |
| Recruiting | Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Immunotherapy Gastrict Cancer | Phase 2 / Phase 3 | 2023-05-10 |
| Unknown | Oncorine (H101) Combined With Tislelizumab and Chemotherapy in Previously Untreated Advanced Non-small Cell Lu Untreated Advanced Non-small Cell Lung Cancer | Phase 1 / Phase 2 | 2023-05-09 |
| Not Yet Recruiting | The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Rectal Cancer | Phase 2 | 2023-05-01 |
| Unknown | Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Colorectal Cancer | Phase 2 | 2023-04-05 |
| Recruiting | Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab Gastric Cancer Stage IV | Phase 1 / Phase 2 | 2023-02-16 |
| Unknown | Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Malignant Melanoma, Liver Metastases | Phase 2 | 2023-02-01 |
| Recruiting | Nituzumab Plus Serplulimab Combined With SBRT in Cervical Cancer Cervical Cancer | Phase 2 | 2023-02-01 |
| Unknown | HRQOL in Locally Advanced Thyroid Carcinoma Thyroid Cancer, Tyrosine Kinase Inhibitor, Health Related Quality of Life | — | 2023-02-01 |
| Unknown | A Study of Eribulin-Based Regimen Versus Other Chemotherpy in Triple-Negative Metastatic Breast Cancer (ERI-Ba Breast Cancer | — | 2023-02-01 |
| Unknown | Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma Lung Adenocarcinoma, Stage IV Non-small Cell Lung Cancer, PD-1 Inhibitor | Phase 2 | 2023-01-10 |
| Unknown | Almonertinib Plus Metronomic Oral Vinorelbine EGFR, NSCLC, Third-generation TKI | — | 2022-12-20 |
| Unknown | TIL Cells for the Treatment of the Advanced Solid Tumors Patients Solid Tumor | EARLY_Phase 1 | 2022-12-05 |
| Unknown | Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer Small Cell Lung Cancer, Angiogenesis, Chemotherapy Effect | Phase 2 | 2022-12-01 |
| Unknown | TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid Tumors Solid Tumors | EARLY_Phase 1 | 2022-12-01 |
| Unknown | Fluzopari Combined With Apatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer Ovarian Cancer | Phase 2 | 2022-11-01 |
| Unknown | An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant Melanom Malignant Melanomas | Phase 1 | 2022-10-27 |
| Unknown | Phase Ⅰa Clinical Study of Hawthorn Red Pigment Combined With Standard Analgesic for Refractory Cancer Pain Hawthorn Red Combined Refractory Cancer Pain | Phase 1 | 2022-10-01 |
| Unknown | Elective Level Ib Irradiation in Nasopharyngeal Carcinoma Patients Based on the International Guidelines Nasopharyngeal Carcinoma | Phase 3 | 2022-09-16 |
| Unknown | the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation Non-small Cell Lung Cancer Confirmed by Histopathology or Cytology, The TNM (8th) Phase is IV, With EGFR Mutations | — | 2022-09-01 |
| Unknown | To Determine the Efficacy and Safety of Envafolimab Combined With XELOX for Locally Advanced Colon Cancer Colon Cancer | Phase 2 | 2022-05-01 |
| Unknown | TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Immunotherapy, Colorectal Cancer | Phase 2 | 2022-04-01 |
| Unknown | the Role of ctDNA in Predicting the Recurrence Risk of Colorectal Cancer Colorectal Cancer Stage II, Colorectal Cancer Stage III | N/A | 2021-12-01 |
| Unknown | Effects of Mobile Medicine on Cancer Patients Cancer Pain | N/A | 2021-11-01 |
| Completed | Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrm Immunotherapy, Gastrict Cancer | Phase 2 | 2021-10-31 |
| Unknown | Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II Study Advanced Colorectal Cancer | Phase 2 | 2021-10-13 |
| Unknown | Tislelizumab as Cross-line Treatment for Advanced NSCLC Advanced Non-small-cell Lung Cancer | Phase 2 | 2021-10-10 |
| Recruiting | Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer Advanced Triple Negative Breast Cancer | Phase 1 / Phase 2 | 2021-10-01 |
| Unknown | Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancer Metastatic Colorectal Cancer | Phase 2 | 2021-10-01 |
| Withdrawn | Study of FMT Combined With Nivolumab in Gastric Cancer Gastric Adenocarcinoma, Esophagogastric Junction Adenocarcinoma, Esophagus Adenocarcinoma | N/A | 2021-10-01 |
| Unknown | Short-term Outcomes of SILS+1 Versus CLS for Distal Gastric Cancer Surgery | Phase 3 | 2021-10-01 |
| Unknown | PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Es Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma | Phase 2 | 2021-08-15 |
| Unknown | Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma Nasopharyngeal Carcinoma | Phase 2 | 2021-08-01 |
| Completed | IV PCA With or Without Continuous Dose vs Oral Opioid to Maintain Analgesia for Severe Cancer Pain After Succe Cancer Pain | Phase 3 | 2021-07-01 |
| Unknown | Almonertinib as First-line Treatment in Patients With EGFR+ Positive Pulmonary Adenosquamous Carcinoma or Comb Pulmonary Adenosquamous Carcinoma | Phase 2 | 2021-05-07 |
| Unknown | Using Mini Program for Self-management VS Conventional Pharmaceutical Care for Cancer Pain Cancer Pain | N/A | 2021-05-01 |
| Unknown | Evaluating the Rationality of the International Guideline About Selective Coverage of Level Ib in CTV With NPC Nasopharyngeal Carcinoma | — | 2021-05-01 |
| Unknown | Second-line Surufatinib Combined With Chemotherapy in Advanced CRC Advanced Colorectal Cancer | Phase 2 | 2021-03-01 |
| Unknown | Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemo NSCLC Stage IV | Phase 2 | 2020-12-01 |
| Unknown | Opioid Titration With 12.5 ug/h Fentanyl Transdermal Patch vs Orally Morphine for Opioid-naïve Patients With M Opioid, Moderate Cancer Pain, Transdermal Fentanyl, 12.5ug/h, Opioid-naive | Phase 3 | 2020-09-01 |
| Unknown | Triprilimab(JS001) and Chemotherapy Combined With Local Treatment for Multiple Metastatic NPC Nasopharyngeal Carcinoma | Phase 2 | 2020-06-15 |
| Unknown | Sufficient Chemotherapy Combine With Maintenance Chemotherapy in the Treatment of Oligometastatic Nasopharynge Nasopharyngeal Carcinoma | Phase 2 | 2020-06-01 |
| Completed | To Evaluate the Efficacy and Feasibility of Modified Reduce-volume Target IMRT in the Treatment of Patients Wi Nasopharyngeal Carcinoma | — | 2020-06-01 |
| Completed | Intravenous vs Oral Analgesia in Cancer Patients With Severe Pain After Successful Titration Cancer Pain | Phase 2 | 2020-04-10 |
| Unknown | PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer Advanced Gastric Adenocarcinoma | N/A | 2019-12-10 |
| Unknown | Study of the Apatinib Combine With POF Versus POF in Gastric Cancer Gastric Adenocarcinoma, Advanced Cancer | Phase 2 | 2019-12-01 |
| Unknown | Radical Radiotherapy and Chemotherapy Combined With Maintenance Chemotherapy in the Treatment of Stage N3 NPC Nasopharyngeal Carcinoma | Phase 2 | 2019-12-01 |
| Unknown | Apatinib Plus Sintilimab in Advanced Gastric Cancer Refractory to at Least Two Previous Chemotherapy Regimens Advanced Metastatic Gastric Cancer | Phase 2 | 2019-12-01 |
| Unknown | POF Versus FOLFOX Plus IP Paclitaxel in AGC Gastric Cancer | Phase 2 | 2019-12-01 |
| Unknown | Neoadjuvant POF in the Treatment of Locally Advanced Gastric Cancer Gastric Cancer | Phase 2 | 2019-11-01 |
| Unknown | A Randomized Phase III Study Comparing POF With SOX/CAPOX/FOLFOX as a Postoperative Adjuvant Chemotherapy for Gastric Cancer Stage III | Phase 3 | 2019-02-01 |
| Unknown | Apatinib Combined With POF for Second-line Treatment of Gastric Adenocarcinoma Gastric Adenocarcinoma | Phase 2 | 2019-02-01 |
| Unknown | Study of the Combination of Apatinib and POF Gastric Adenocarcinoma | Phase 2 | 2018-11-01 |
| Withdrawn | Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients Colorectal Adenocarcinoma | Phase 3 | 2018-11-01 |
| Withdrawn | Change the Dose Frequency of Controlled-Release Oxycodone to Refractory Pain Cancer Pains | Phase 4 | 2018-10-30 |
| Unknown | EBV-TCR-T（YT-E001）for Patients With EBV-positive Recurrent or Metastatic NPC Nasopharyngeal Carcinoma | Phase 2 | 2018-10-10 |
| Unknown | EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSC EGFR Gene Mutation | Phase 2 | 2018-10-01 |
| Completed | PCA vs Non-PCA Intravenous Hydromorphone Titration for Severe Cancer Pain Cancer Pain | Phase 3 | 2018-09-29 |
| Unknown | Cognitive Dysfunction in Patients With Cancer Pain Cognitive Dysfunction | — | 2018-08-21 |
| Unknown | Phase I Study of the Combination of Anlotinib With Pemetrexed or Docetaxel Non-squamous Non-small Cell Lung Cancer | N/A | 2018-07-01 |
| Unknown | Next-generation Sequencing in Gastrointestinal Cancer Gastrointestinal Cancer | — | 2018-07-01 |
| Unknown | Appaconitine Patch for Oral Mucositis Pain Caused by Chemoradiotherapy in Patients With Nasopharyngeal Cancer Radiation Induced Oral Mucositis | N/A | 2018-07-01 |
| Unknown | Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation Lung Adenocarcinoma, EGFR Mutation | Phase 2 | 2018-06-05 |
| Unknown | Afatinib Plus Chemotherapy Against Esophageal or Lung Squamous Cell Carcinoma Squamous Cell Carcinoma | Phase 2 | 2018-04-01 |
| Withdrawn | Phase I Study of Biweekly SIRB Regimen for Metastatic Colorectal Cancer Metastatic Colorectal Cancer | Phase 1 | 2018-01-05 |
| Completed | Effects of Anesthesia on Tumor Immunity and Insulin Resistance During Perioperative Period Anesthesia, Cervical Cancer, Carbohydrate | N/A | 2018-01-01 |
| Unknown | Phase I Study of the Combination of Apatinib and POF Gastric Adenocarcinoma | Phase 1 | 2018-01-01 |
| Unknown | Next-generation Sequencing of Small Cell Lung Cancer to Identify Susceptibility Gene and to Assess Treatment SCLC | — | 2017-11-01 |
| Withdrawn | Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC Metastatic Colorectal Cancer | Phase 2 | 2017-07-20 |
| Unknown | Docetaxel and S-1 Combination Therapy as Second-line Treatment for Advanced Gastric Cancer Advanced Gastric Cancer | Phase 2 | 2017-06-01 |
| Unknown | EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide NSCLC Stage IV, Chemotherapy Effect | Phase 2 | 2017-04-01 |
| Unknown | mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction | N/A | 2017-02-10 |
| Unknown | Clinical Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in AGC or Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction | Phase 2 | 2017-02-01 |
| Unknown | The Efficacy and Safety of Endostar Combined With Taxane-based Regimens for HER-2-negative MBC Patients Angiogenesis, Breast Cancer | Phase 3 | 2016-12-01 |
| Unknown | Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer Malignant Neoplasm of Stomach Stage II | Phase 2 | 2016-08-01 |
| Unknown | EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC EGFR Gene Mutation | Phase 3 | 2016-07-01 |
| Completed | POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel in AGC Malignant Neoplasm of Stomach Stage IV | Phase 2 | 2015-11-01 |
| Unknown | Comparison of Short Term Outcomes Between Totally Laparoscopic and Laparoscopy-Assisted Distal Gastrectomy Wit Total Laparoscopic Distal Gastrectomy, Locally Advanced Gastric Cancer | N/A | 2015-06-01 |
| Unknown | Nimotuzumab for Recurrent Nasopharyngeal Carcinoma Recurrent Nasopharyngeal Carcinoma | Phase 2 | 2014-11-01 |
| Completed | Intensity Modulated Radiotherapy in Recurrent T1-2 Nasopharyngeal Carcinoma Nasopharyngeal Cancer Recurrent | N/A | 1996-01-01 |